Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) pipeline Target constitutes close to 35 molecules. Out of which approximately 32 molecules are developed by companies and remaining by the universities/institutes. The latest report Fibroblast Growth Factor Receptor 4 - Drugs In Development, 2022, outlays comprehensive information on the Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Fibroblast growth factor receptor 4 is a protein encoded by the FGFR4 gene. It plays a role in the regulation of cell proliferation, differentiation, and migration, and in regulation of lipid metabolism, bile acid biosynthesis, glucose uptake, vitamin D metabolism and phosphate homeostasis. It is required for normal down-regulation of the expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis, in response to FGF19. It phosphorylates PLCG1 and FRS2. Ligand binding leads to the activation of several signaling cascades. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 5, 6, 3, 8 and 4 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 2 molecules, respectively.

Report covers products from therapy areas Oncology, Gastrointestinal, Metabolic Disorders, Musculoskeletal Disorders, Central Nervous System, Infectious Disease and Undisclosed which include indications Hepatocellular Carcinoma, Solid Tumor, Bile Duct Cancer (Cholangiocarcinoma), Gastric Cancer, Breast Cancer, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Adenocarcinoma Of The Gastroesophageal Junction, Glioblastoma Multiforme (GBM), Lung Adenocarcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Prostate Cancer, Thyroid Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Achondroplasia, Adenoid Cystic Carcinoma (ACC), Adrenocortical Carcinoma (Adrenal Cortex Cancer), Bladder Cancer, Gastrointestinal Stromal Tumor (GIST), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Liver Cancer, Muscle Invasive Bladder Cancer (MIBC), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Ovarian Cancer, Rhabdomyosarcoma, Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, Type 2 Diabetes, Anaplastic Thyroid Cancer, Bladder Carcinoma, Childhood Rhabdomyosarcoma, Colorectal Cancer, Constipation, Diarrhea, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Ewing Sarcoma, Extrahepatic Bile Duct Cancer, Fallopian Tube Cancer, Gallbladder Cancer, Gastrointestinal Tract Cancer, High-Grade Glioma, Human Papillomavirus Infections, Hypopharyngeal Cancer, Kidney Cancer (Renal Cell Cancer), Laryngeal Cancer, Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Liver Cirrhosis, Liver Fibrosis, Low-Grade Glioma, Lymphoma, Malignant Pleural Mesothelioma, Melanoma, Merkel Cell Carcinoma, Metastatic Bile Duct Cancer, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Neuroendocrine Carcinoma, Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Obesity, Oral Cavity (Mouth) Cancer, Oral Mucositis, Oropharyngeal Cancer, Osteosarcoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Paranasal Sinus And Nasal Cavity Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Peritoneal Cancer, Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Primary Sclerosing Cholangitis, Primitive Neuroectodermal Tumor (PNET), Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Salivary Gland Cancer, Sarcomas, Spinal Cord Injury, Squamous Cell Carcinoma, Thymic Carcinoma, Triple-Negative Breast Cancer (TNBC), Unspecified, Ureter Cancer and Urethral Cancer.

Furthermore, this report also reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
• The report reviews Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
• The report assesses Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) targeted therapeutics

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned
Companies Mentioned

Abbisko Therapeutics Co Ltd
Applied Pharmaceutical Science Inc
Astellas Pharma Inc
Bayer AG
Betta Pharmaceuticals Co Ltd
BioArdis LLC
Blueprint Medicines Corp
BridgeBio Pharma Inc
BridGene Biosciences Inc
Bristol-Myers Squibb Co
Eddingpharm Inc
Eisai Co Ltd
Eli Lilly and Co
EUSOL Biotech Co Ltd
Everest Medicines Ltd
Genosco Inc
H3 Biomedicine Inc
Heilongjiang ZBD Pharmaceutical Co Ltd
ImmunoForge Co Ltd
InnoCare Pharma Ltd
Jacobio Pharmaceuticals Group Co Ltd
Johnson & Johnson
Merck & Co Inc
NGM Biopharmaceuticals Inc
Shouyao Holding Co Ltd
Tyra Biosciences Inc
Vichem Chemie Research Ltd
Zhejiang Hisun Pharmaceutical Co Ltd